Gilles Gagnon M.Sc., MBA (President and Chief Executive Officer)
Mr. Gilles Gagnon is the President and Chief Executive Officer of Ceapro Inc. He has also been President of Prodev Pharma Inc. since May 2007. Prior to that, he was Chief Executive Officer of AEterna Zentaris. During the past thirty years, Mr. Gagnon has worked at several management levels within the field of health, especially in the hospital environment and pharmaceutical industry where he participated in launching several new pharmaceutical products. Before coming to AEterna in 1999, Mr. Gagnon was Vice President, External Affairs, for Novartis Pharma Canada Inc. Mr. Gagnon holds a Master’s degree in Pharmacology (M.Sc.), a Master’s degree in Business Administration (MBA) from Sherbrooke University, and a certificate in general management from the London Business School, UK.
Branko Jankovic, CA (Chief Financial Officer and Vice President, Finance)
Mr. Jankovic is responsible for all required corporate and financial reporting, as well as management of all administration departments. He has 25 years of finance and business experience. Prior to working at Ceapro, Mr. Jankovic was a business consultant providing consulting services to public, private, and government clients. Mr. Jankovic graduated from Lakehead University in 1983 with a Bachelor’s Degree in Commerce and was awarded the Dean Braun medal for top standing. He articled with Collins Barrow in Edmonton and obtained the Chartered Accountant designation in 1985 from the Institute of Chartered Accountants in Alberta.
David Fielder, M.Sc. (Chief Scientific Officer)
Mr. Fielder is the Chief Scientific Officer of Ceapro Inc. Originally from Ottawa, he earned his M.Sc. in Natural Products Chemistry at Carlton University in Ottawa in 1988. Thereafter he joined the federal department of Agriculture and Agri-Food Canada as a research chemist isolating and characterizing new molecules from various plant and fungal species.
In 1996, while working as a Research Associate for Ceapro Developments Inc., Mr. Fielder was responsible for identifying and developing new oat extracts and first identified the link between the traditional use of colloidal oatmeal for treatment of various skin ailments and naturally occurring avenanthramides. Since then, he has been responsible for new product development as well as commercial scale-up of Ceapro’s products into the global markets of veterinary medicine, personal care, industrial, and medical products.
Due to his solid scientific background, leadership skills, and hands-on business and marketing experience, Mr. Fielder is now responsible for product research and development, as well as marketing & business development.